MediWound Ltd. (NASDAQ: MDWD)

MediWound Ltd. is a global leader in next generation enzymatic therapeutics focused on non surgical tissue repair. The company develops and commercializes biologics for wound and burn care, aiming to replace surgical debridement with enzymatic alternatives.

MediWound generates revenue primarily from product sales of NexoBrid, royalties and milestone payments under its license agreement with Vericel for North America, and government funding for development programs such as BARDA and DoW/MTEC contracts. The company also receives grant funding and collaboration support. Its customers include hospitals, burn centers, wound care clinics, and government agencies.

MediWound holds a leading position in the enzymatic debridement market for burn and wound care. Its flagship product NexoBrid competes against traditional surgical methods such as tangential excision and dermabrasion, as well as non surgical enzymatic agents like Smith & Nephew’s SANTYL. Competitive advantages include the product’s ability to selectively remove non viable tissue while preserving healthy tissue, its orphan drug status in the United States, strong patent protection, and support from government agencies such as BARDA.

MediWound’s customers include hospitals, burn centers, and wound care clinics that purchase NexoBrid directly or through distributors. Key partners and collaborators are Vericel, BARDA, the Department of Defense, Coloplast, B. Braun, Convatec, Essity, Mölnlycke, Solventum, and MiMedx. These relationships support product development, clinical trials, and commercialization efforts.